Management of childhood psoriasis (Q37405409)

20 August 2017

1 reference

title

Management of childhood psoriasis. (English)

1 reference

20 August 2017

Kelly M Cordoro

1

0 references

publication date

1 January 2008

1 reference

20 August 2017

published in

Advances in dermatology

1 reference

20 August 2017

volume

24

1 reference

20 August 2017

page(s)

125-169

1 reference

A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Epidemiology of childhood psoriasis: a study of 419 patients from northern India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Pediatric psoriasis and psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Childhood psoriasis: a clinical review of 1262 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A comparative study of pediatric onset psoriasis with adult onset psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Management of psoriasis in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasiform napkin dermatitis—a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Infantile psoriasis: a follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The role of immune system in the pathogenesis of psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Skin T cell proliferative response to M protein and other cell wall and membrane proteins of group A streptococci in chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Non-M protein(s) on the cell wall and membrane of group A streptococci induce(s) IFN-gamma production by dermal CD4 T cells in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriatic eruption in Kawasaki disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A case of guttate psoriasis following Kawasaki disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Natural history of psoriasis in 61 twin pairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Identifying a gene for psoriasis on chromosome 6 (Psors1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

HLA risk haplotype Cw6,DR7,DQA1*0201 and HLA-Cw6 with reference to the clinical picture of psoriasis vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

Psoriasis and HLA-Cw6

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Suprabasal integrin expression in the epidermis of transgenic mice results in developmental defects and a phenotype resembling psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasis: advances in pathophysiology and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasis of early and late onset: A clinical and epidemiologic study from Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasis and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Association between psoriasis and the metabolic syndrome. A cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

HLA-C and guttate psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

How Great Is the Risk of Further Psoriasis Following a Single Episode of Acute Guttate Psoriasis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The T4 lymphocyte in AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Acquired immunodeficiency syndrome (AIDS) can exacerbate psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasis in children: a guide to its diagnosis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Correlation of the vasoconstriction assay and clinical activity in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Issues in measuring percutaneous absorption of topical corticosteroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A clinician's paradigm in the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tachyphylaxis to topical corticosteroids: the more you use them, the less they work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasis. A review of recent advances in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

New coal tar extract and coal tar shampoos. Evaluation by epidermal cell DNA synthesis suppression assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Crude Coal Tar Plus Near Ultraviolet Light Suppresses DNA Synthesis in Epidermis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Coal tar therapy. Is it carcinogenic?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Anthralin: historical and current perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The approach to psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Anti-Psoriatic Drug Anthralin Activates JNK via Lipid Peroxidation: Mononuclear Cells are More Sensitive than Keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Efficacy of short-contact therapy with dithranol in childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Short-duration ('minutes') therapy with dithranol for psoriasis: a new out-patient regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

An open assessment of 0.1% dithranol in a 17% urea base (‘Psoradrate' 0.1%) in the treatment of psoriasis of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Treatment of psoriasis. Part 1. Topical therapy and phototherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Topical calcipotriol in childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Infantile psoriasis: successful treatment with topical calcipotriol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Response of psoriasis to a new topical retinoid, AGN 190168

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Early clinical development of tazarotene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Childhood Nail Psoriasis: A Useful Treatment with Tazarotene 0.05%

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: are they effective?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Topical tacrolimus for facial psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tacrolimus ointment is effective for facial and intertriginous psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Successful treatment with topical tacrolimus for oral psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Topical tacrolimus in the treatment of inverse psoriasis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Percutaneous Absorption of Salicylic Acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Treatment of psoriasis. Part 2. Systemic therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A review of acitretin, a systemic retinoid for the treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Etretinate in severe psoriasis of children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Etretinate therapy for generalized pustular psoriasis in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Childhood generalized pustular psoriasis: successful treatment with isotretinoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Oral retinoid therapy for dermatologic conditions in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Ocular side effects of the retinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Variations in lipid and lipoprotein levels during isotretinoin treatment for acne vulgaris with special emphasis on HDL‐cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Rheumatologic complications of vitamin A and retinoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The use of retinoids in the pediatric patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Efficacy and safety of oral retinoids in psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Premature epiphyseal closure--a complication of etretinate therapy in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Oral retinoid therapy for disorders of keratinization: single-centre retrospective 25 years' experience on 23 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Noninvasive monitoring for methotrexate hepatotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The mechanism of action of methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Methotrexate in childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Dermatologic uses of methotrexate in children: indications and guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Intestinal function and methotrexate absorption in psoriatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Methotrexate in severe childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Erythrodermic psoriasis in childhood. A young Negro child treated with methotrexate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Folic acid in general medicine and dermatology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Methotrexate in psoriasis: Consensus conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Treatment of severe atopic dermatitis in childhood with cyclosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Cyclosporin A treatment in severe childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Laboratory monitoring of cyclosporine levels: guidelines for the dermatologist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The use of cyclosporin in a child with generalized pustular psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Low dose cyclosporin A treatment in generalized pustular psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Safety issues with cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Narrowband ultraviolet B therapy for psoriasis and other skin disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Narrow-band UV-B phototherapy in childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Experience with UVB phototherapy in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

UVB phototherapy in childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Phototherapy in pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A randomized controlled trial of narrowband ultraviolet B vs bath-psoralen plus ultraviolet A photochemotherapy for psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Action Spectrum for Phototherapy of Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

311 nm UVB phototherapy--an effective treatment for psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

History of psoriasis response to sunlight does not predict outcome of UVB phototherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A positive correlation between history of psoriasis response to sunlight and the response to UVB phototherapy. What are the consequences?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Clinical efficacy of narrow-band UVB (311 nm) combined with dithranol in psoriasis. An open pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Interactions between calcipotriene and ultraviolet light

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Retrospective study of the efficacy of narrowband UVB and acitretin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Blisters on psoriatic lesions treated with TL-01 lamps

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Lesional blistering following narrow-band (TL-01) UVB phototherapy for psoriasis: a report of four cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The challenge of follow-up in narrowband ultraviolet B phototherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Bath PUVA and saltwater baths followed by UV-B phototherapy as treatments for psoriasis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Side-effects of psoralen photochemotherapy (PUVA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Bath PUVA and psoriasis: is a milder treatment a worse treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Retrospective analysis of the treatment of psoriasis of the palms and soles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Treatment of erythrodermic psoriasis with etanercept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Etanercept for psoriasis in the pediatric population: experience in nine patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Etanercept for the treatment of severe childhood psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Successful treatment of pediatric psoriasis with infliximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Anti-TNF-α Therapy in Childhood Pustular Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Guttate psoriasis associated with perianal streptococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

Psoriasis in children

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Clinical Response of a Human IL-12 p40 Antibody in Subjects with Plaque Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Dithranol allergy: fact or fiction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

Coal tar therapy in palmoplantar psoriasis: old wine in an old bottle?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

The natural history of psoriasis in 5,600 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YADR.2008.09.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YADR.2008.09.009

1 reference

20 August 2017

1 reference